Shots:
- Biocon Biologics revealed positive results from the P-III study demonstrating that Yesintek achieved equivalent efficacy, safety, immunogenicity, and PK vs reference product to treat mod. to sev. chronic plaque psoriasis (PsO) pts. (n=384, age= 18-80yrs.); data was presented at AAD 2025
- The primary efficacy endpoint, percentage change in PASI scores at Wk. 12 showed similar improvement, with a mean difference of 0.68%, within predefined equivalence margins of the US FDA & EMA. Switching from Stelara to YESINTEK at Wk. 16 maintained efficacy & safety through Wk. 52
- Yesintek (mAb) targets interleukins IL-12 and IL-23, approved for the treatment of Crohn’s disease, Ulcerative Colitis, PsO and Psoriatic Arthritis
Ref: Biocon Biologics| Image: Biocon Biologics| Press Release
Related News:- Biocon Biologics Launches Yesintek (Biosimilar, Stelara) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
